RxDoctor Payments Data

Ivy Enger

Family · Naperville, ILNPI 1003348103

Payments from drug & device makers

$1,199in general payments, 2019–2025

Across 52 payments — averaging $23.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$374
  • Dexcom, Inc.$316
  • Abbott$173
  • Antares Pharma, Inc.$145
  • Tandem Diabetes Care, Inc.$95
  • Lilly USA, LLC$30
  • plus $66 from 3 others

What the payments were for

  • Food & beverage$1,13595%
  • Education$655%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,199 in reported general payments places this provider in the 75th percentile of 4,941 family providers in Illinois.

See all family providers in Illinois

Medicare billing

Part B allowed, 2024
$26,191
Medicare patients
114
Services billed
384

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide59$75,679
TrulicityDulaglutide45$72,671
RybelsusSemaglutide38$68,010
JardianceEmpagliflozin32$46,835
MounjaroTirzepatide32$30,489
FarxigaDapagliflozin Propanediol17$19,018
Humalog Kwikpen U-100Insulin Lispro21$12,368
JanuviaSitagliptin Phosphate15$11,088
Lantus SolostarInsulin Glargine,hum.Rec.Anlog71$8,761
Gvoke Hypopen 2-PackGlucagon11$6,802
Tresiba Flextouch U-100Insulin Degludec11$5,732
Nano 2nd Gen Pen NeedlePen Needle, Diabetic46$5,343
Novolog FlexpenInsulin Aspart21$5,228
SynthroidLevothyroxine Sodium12$1,299
Metformin Hcl ErMetformin Hcl67$798

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$374$143,68997 claims
Lilly USA, LLCTrulicity, Mounjaro$30$103,16077 claims
AbbVieSynthroid$19$1,29912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,941 family providers in Illinois.

Other family in Naperville

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →